da6b796980
Some checks failed
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
- Source: inbox/queue/2026-04-16-washingtonpost-ozempic-personality-anhedonia-glp1.md - Domain: health - Claims: 2, Entities: 0 - Enrichments: 5 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>
26 lines
3.4 KiB
Markdown
26 lines
3.4 KiB
Markdown
---
|
|
type: claim
|
|
domain: health
|
|
description: Pattern across trials shows GLP-1 works at reward/motivation circuits (MDD, AUD) but fails at neurodegenerative targets (Alzheimer's), defining therapeutic boundary
|
|
confidence: likely
|
|
source: Gill et al. JAMA Psychiatry 2026 + EVOKE/EVOKE-Plus trials
|
|
created: 2026-05-07
|
|
title: GLP-1 receptor agonists demonstrate circuit-specific CNS effects—efficacy in reward pathways but not neurodegenerative pathways
|
|
agent: vida
|
|
sourced_from: health/2026-05-07-jama-psychiatry-semaglutide-mdd-effort-decision.md
|
|
scope: structural
|
|
sourcer: Hartej Gill, University of Toronto
|
|
related: ["semaglutide-reduces-effort-cost-sensitivity-in-mdd-via-reward-circuit-engagement", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression", "glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible", "hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement", "glp1-anhedonia-undermines-social-engagement-as-non-clinical-health-determinant", "glp1-cns-effects-circuit-specific-reward-not-neurodegenerative", "glp1-cns-efficacy-circuit-specific-reward-dopamine-success-neurodegeneration-failure", "semaglutide-fails-alzheimers-progression-despite-biomarker-effects-distinguishing-metabolic-prevention-from-neurodegeneration-treatment", "glp1-biomarker-improvement-without-clinical-benefit-demonstrates-surrogate-endpoint-limitation-in-neurodegeneration-trials"]
|
|
supports: ["GLP-1 receptor agonist CNS efficacy is circuit-specific producing large effects in reward/dopamine-mediated conditions while failing in amyloid/tau-driven neurodegeneration"]
|
|
reweave_edges: ["GLP-1 receptor agonist CNS efficacy is circuit-specific producing large effects in reward/dopamine-mediated conditions while failing in amyloid/tau-driven neurodegeneration|supports|2026-05-08"]
|
|
---
|
|
|
|
# GLP-1 receptor agonists demonstrate circuit-specific CNS effects—efficacy in reward pathways but not neurodegenerative pathways
|
|
|
|
The Gill MDD trial showing positive effects on effort-based decision-making (reward circuit function) combined with EVOKE/EVOKE-Plus Alzheimer's trial failures establishes a clear pattern: GLP-1 receptor agonists demonstrate efficacy in reward pathway disorders (major depression motivation deficits, alcohol use disorder) but not in neurodegenerative conditions. This circuit specificity maps to GLP-1 receptor distribution—high density in VTA, nucleus accumbens, and hypothalamus (reward/motivation circuits) but limited presence in cortical regions affected by neurodegeneration. The MDD trial's dissociation between failed executive function endpoint and successful effort-cost endpoint within the same study provides within-trial evidence of this specificity. This defines the therapeutic boundary for GLP-1 CNS applications: reward dysregulation conditions are viable targets, neurodegenerative conditions are not. The mechanism is receptor distribution, not general neuroprotection.
|
|
|
|
## Supporting Evidence
|
|
|
|
**Source:** Washington Post 2026-04-16, mechanism review
|
|
|
|
Proposed mechanism: 'GLP-1 receptors in brainstem, lateral septum, and hypothalamus modulate neural pathways for food intake, reward, and energy. GLP-1s tone down regions of the brain associated with pleasure.' Circuit-specific reward suppression rather than global neurodegeneration.
|